NCT05641428View on ClinicalTrials.gov

Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
NHLDLBCL - Diffuse Large B Cell Lymphoma
Interventions
DRUG

ARI-0001

Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).

DRUG

Axi-cel

Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).

Trial Locations (7)

Unknown

RECRUITING

NL-Amsterdam-AMC, Amsterdam

RECRUITING

NL-Groningen-UMCG, Groningen

RECRUITING

NL-Leiden-LUMC, Leiden

RECRUITING

NL-Maastricht-MUMC, Maastricht

RECRUITING

NL-Nijmegen-RADBOUDUMC, Nijmegen

RECRUITING

NL-Rotterdam-ERASMUSMC, Rotterdam

RECRUITING

NL-Utrecht-UMCUTRECHT, Utrecht

All Listed Sponsors
collaborator

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER

lead

University Medical Center Groningen

OTHER